

AstraZeneca plans \$15 B investment in China to expand medicines manufacturing and R&D

January 30, 2026 | News

Landmark investment will expand AstraZeneca's capabilities to discover, develop, and manufacture transformative new treatments in China



AstraZeneca has announced \$15 billion investment in China through 2030 to expand medicines manufacturing and R&D. This investment will leverage the country's scientific excellence, advanced manufacturing, and China-UK healthcare ecosystem collaborations to deliver cutting-edge treatments to patients across China and globally.

Recognising China's advanced science in new modalities, this investment will significantly enhance the company's cell therapy and radioconjugates capabilities that are driving its broad and varied pipeline to help patients with cancer, haematological conditions and autoimmune diseases, among others.

These investments span the value chain, from drug discovery and clinical development to manufacturing, and bring Chinese innovation to the world through our partnerships with leading biotechs including AbelZeta, CSPC, Harbour BioMed, Jacobio and Syneron Bio. Building on the 2024 acquisition of Gracell Biotechnologies, AstraZeneca will also become the first global biopharmaceutical leader with end-to-end cell therapy capabilities in China.

These investments build on AstraZeneca's substantial R&D footprint, including global strategic R&D centres in Beijing and Shanghai, which collaborate with over 500 clinical hospitals, and have led on a large number of global clinical trials in the past three years alone.

The company will also develop its existing manufacturing facilities in Wuxi, Taizhou, Qingdao, and Beijing, which provide high-quality medicines to patients in China and 70 markets worldwide, together with the establishment of new sites to be announced. Together, these investments will grow the Company's highly skilled workforce in China beyond 20,000 and create thousands of additional jobs across the healthcare ecosystem.

The investment, announced during the UK Prime Minister's visit to China, will strengthen China-UK collaboration in healthcare innovation and will benefit the life sciences ecosystems of both countries. Building on its successful ecosystem collaboration

with the University of Cambridge and Beijing, AstraZeneca is working with other pre-eminent research and financial institutions - including the University of Oxford, the University of Glasgow, King's College London, and HSBC - to establish further collaborations between dynamic ecosystems in both countries.